Fibrinolytic shutdown: Fascinating theory but randomized controlled trial data are needed

Transfusion

Volumn 56, Issue , 2016, Pages S115-S118

  Roberts, Ian ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ARTICLE; BLEEDING; DEATH; FIBRINOLYSIS; HUMAN; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; THROMBOELASTOGRAPHY; TIME TO TREATMENT; HEMORRHAGE; INJURY SCALE;

ANTIFIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INJURY SEVERITY SCORE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANEXAMIC ACID;

EID: 84964397453     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13490     Document Type: Article

References (14)

1. CRASH-2 trial collaborators, Shakur H, Roberts I, et al., Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
2. CRASH-2 collaborators, Roberts I, Shakur H, et al., The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377: 1096-101, 1101.e1-2.
3. Roberts I, Prieto-Merino D, Manno D., Mechanism of action of tranexamic acid in bleeding trauma patients: an exploratory analysis of data from the CRASH-2 trial. Crit Care 2014; 18: 685. doi: 10.1186/s13054-014-0685-8.
4. Chapman M, Moore E, Ramos C, et al., Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy. J Trauma Acute Care Surg 2013; 75: 961-7.
5. Moore E, Moore H, Gonzalez E, et al., Postinjury fibrinolysis shutdown: rationale for selective tranexamic acid. J Trauma Acute Care Surg 2015; 78 (6 Suppl 1): S65-9.
6. Gando S, Sawamura S, Hayakawa M., Trauma, shock, and disseminated intravascular coagulation. Ann Surg 2011; 254: 10-9. doi: 10.1097/SLA.0b013e31821221b1.
7. Sawamura A, Hayakawa M, Gando S, et al., Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. Thromb Res 2009; 124: 608-13. doi: 10.1016/j.thromres.2009.06.034.
8. Roberts I, Perel P, Prieto-Merino D, et al., Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. BMJ 2012; 345: e5839. doi: 10.1136/bmj.e5839.
9. Ker K, Kiriya J, Perel P, et al., Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial. BMC Emerg Med 2012; 12: 3.
10. Roberts I, Prieto-Merino D., Applying results from clinical trials: tranexamic acid in trauma patients. J Intensive Care 2014; 2: 56. doi: 10.1186/s40560-014-0056-1.
11. Ker K, Edwards P, Perel P, et al., Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012; 344: e3054. doi: 10.1136/bmj.e3054.
12. Ker K, Prieto-Merino D, Roberts I., Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss. Br J Surg 2013; 100: 1271-9. doi: 10.1002/bjs.9193.
13. Ker K, Beecher D, Roberts I., Topical application of tranexamic acid for the reduction of bleeding. Cochrane Database Syst Rev 2013; 7: CD010562.
14. Roberts I., Tranexamic acid in trauma: how should we use it? J Thromb Haemost 2015; 13 (Suppl 1): S195-9. doi: 10.1111/jth.12878.